AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05284409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 36 patients will receive 15 mg/kg Acetaminophen IVI
Study NCT05284409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 36 patients will receive 0.1 mg/kg Dexamethasone IVI
Study NCT03463239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tissue engineered corpora
Description: penile tissue construct
Study NCT04781855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT04781855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04781855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05660785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT.~Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.
Study NCT06498648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT06498648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06498648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06498648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06498648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06498648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT06498648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV
Study NCT06498648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06498648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT06498648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05966181 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: experimental group
Description: Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation.
Study NCT05966181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation.
Study NCT06492616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Administered as oral tablets
Study NCT06492616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Administered as oral tablets
Study NCT05208515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: independent obsteric operating center
Description: send emergency cesarean section needing women from labor room to independent obstetric operating center
Study NCT06492616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Administered as oral tablets
Study NCT06492616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Administered as oral tablets
Study NCT06326905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Transplant- Open Label Pilot
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations targeting those currently KT inactive will be made on a per-client basis as part of the open-label pilot. We will further refine and develop the intervention by receiving feedback from the open label pilot participants and CAPABLE clinicians who implemented the pilot to gain their perspective of the acceptability and feasibility of implementing the CAPABLE-Transplant intervention. Based on this feedback, the study team will have developed an adapted iteration of the prototype.
Study NCT06326905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPABLE Transplant- Randomized Control Trial
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
Study NCT06326905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPABLE Transplant- Randomized Control Trial
Description: As in CAPABLE, the delivery characteristics of CAPABLE Transplant consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
Study NCT04629547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Description: Suvorexant 20mg will be taken nightly for 24 months.
Study NCT04629547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken nightly for 24 months.
Study NCT05206942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
Study NCT05206942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
Description: Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
Study NCT05206942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Description: Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
Study NCT06273436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H.E.A.R. for Mamas
Description: H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
Study NCT04965246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
Study NCT04965246 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Participants in the usual care group will receive no intervention
Study NCT06558149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Those whose opioids were adjusted according to hemodynamic parameters
Description: Patient who will be adjusted according to hemodynamic parameter
Study NCT06558149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Those whose opioids were adjusted according to NOL monitoring
Description: Patient who will be adjusted according to NOL monitoring
Study NCT05418244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled Isopropyl Alcohol
Description: Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
Study NCT05418244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ondansetron
Description: 4 mg oral disintegrating ondansetron tablet once
Study NCT05418244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
Study NCT05466799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX chemotherapy
Description: Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
Study NCT05179187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Movement task
Description: Computer task with experimental conditions manipulating sensory and motivation cues for movement.
Study NCT05179187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement task
Description: Computer task with experimental conditions manipulating sensory and motivation cues for movement.
Study NCT05623436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing students will be trained through virtual reality.
Description: Nursing students will be trained through virtual reality.
Study NCT05466799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX chemotherapy
Description: Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
Study NCT05466799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSil™
Description: Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
Study NCT04630496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Electronic activity tracker
Study NCT06379971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Study NCT06379971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
Study NCT06488248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Description: The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.
Study NCT06488248 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ventriculoperitoneal shunt (VPS)
Description: The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.
Study NCT06382610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin will be administered in three different forms
Study NCT06382610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin will be administered in three different forms
Study NCT05809167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN+AZA+Modified BUCY
Description: Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days.
Study NCT04937114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barbed suture
Description: Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
Study NCT04937114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbed suture
Description: Experimental: Wound will be closed using unidirectional barbed sutures in muco-gingival surgeries Active Comparator: Wound will be closed using conventional sutures in muco-gingival surgeries
Study NCT05393518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety-induced task
Description: Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
Study NCT05393518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety-induced task
Description: Subjects will be asked to describe their most anxious thoughts and write each of them in a detailed scenario. The scenarios will be based on the answers to the Worry and Anxiety Questionnaire, in order to validate the procedure by a standardized examination. During the task, the scenarios will be successively presented to the subjects, on a digital computer medium in written and oral format. Subjects will be asked to actively focus on these negative thoughts with maximum concern, without seeking to control their emotions.
Study NCT05393518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric assessment
Description: Screening for depression and anxiety
Study NCT05393518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychiatric assessment
Description: Screening for depression and anxiety
Study NCT05013437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evomela
Description: 16 mg/m\^2 Evomela administered one time via a central line
Study NCT05013437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: Next Generation Sequencing
Study NCT05013437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: 10mg once intravenous (IV) within 30 minutes before Evomela
Study NCT05013437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg once orally within 30 minutes before Evomela
Study NCT05013437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg once intravenously within 30 minutes before Evomela
Study NCT04872166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
Study NCT05609864 — intervention group
Intervention type: OTHER
Intervention: Quantification of injectable drugs wastage
Description: Drugs are prescribed at discretion of physicians. For each patient who have anesthesia in the operating room, all labelled syringes having contained drugs (name + dilution) are collected and analyzed.
Study NCT06482853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Study NCT06482853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be used as the placebo comparator.
Study NCT06054178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Intravenous administration of 1 mg/kg. If initial dosing is insufficient, additional doses may be administered up to a total of 3 mg/kg
Study NCT05023486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044 Monotherapy
Description: 1600 mg QD, 2000mg QD, and 2100 mg QD
Study NCT05023486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Therapy
Description: previously initiated per standard of care, at a dose and frequency in accordance with the package insert
Study NCT05208515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: general operating center
Description: send emergency cesarean section needing women from labor room to general operating center
Study NCT04823702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldafermin
Description: Biological: Aldafermin (NGM282) Subcutaneous Injection
Study NCT05023486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044 Combination therapy
Description: 1600 mg QD or 2100 mg QD
Study NCT04932161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium Granules
Description: After degranulation of the intrabony defect, titanium particles will be placed in the defect and will be sutured.
Study NCT04932161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite
Description: After degranulation of the intrabony defect, hydroxyapatite will be placed in the defect and will be sutured.
Study NCT05909098 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous NK cell
Description: autologous NK cell
Study NCT05050604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Alfoscerate 400mg
Description: Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
Study NCT05050604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Choline Alfoscerate 400mg
Description: Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
Study NCT06415292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (clascoterone) 1% cream
Description: Split face. Blinded study treatment product to be applied to the randomized half face
Study NCT06549855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)
Description: 1. Sintilimab or Pembrolizumab 200mg intravenous injection, every 3 weeks~2. MA, 320mg/MPA, 500mg, po, once a day
Study NCT06538077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Branched chain Amino acid
Description: The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 24 weeks
Study NCT06538077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 MG
Description: Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 24 weeks
Study NCT06538077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
Study NCT06538077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BCAA
Description: A placebo comparator of 15 gm of skimmed milk powder will be used.
Study NCT06538077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Rifaximin 550mg
Description: Identical placebo sugar pills will be used as a placebo.